For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Formats:
Features:
Osteoprotegerin (OPG), also known as osteoclastogenesis inhibitory factor, is a human protein encoded by the gene TNFRSF11B (tumor necrosis factor receptor superfamily member 11B). It is a cytokine decoy receptor for nuclear factor kappa B ligand receptor, and neutralizes its function in osteoclastogenesis. Osteoprotegerin-mediated pathways maintain the structure of healthy bone by inhibiting osteoclast activation. It is released as a disulfide-linked homodimer, though the monomeric form is also present in human serum. The OPG pathway poses a potential therapy for osteopenic disorders, such as osteoporosis, arthritis and hypercalcemia. This AlphaLISA kit will detect both the homodimer and the monomeric forms of osteoprotegerin.
AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
Assay Target | Osteoprotegerin |
---|---|
Assay Target Class | Protein |
Automation Compatible | Yes |
Detection Method | Alpha |
Experimental Type | In vitro |
Product Brand Name | AlphaLISA |
Shipping Condition | Blue Ice |
Therapeutic Area | Inflammation |
Unit Size | 5,000 Assay Points |
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.
This manual explains how to run the AlphaLISA no-wash human total osteoprotegerin detection assay.